stockrow
Friday 6 November 2026
Export NEUP’s income statement to Excel — free account
Neuphoria Therapeutics Inc.
NEUP Healthcare Biotechnology
Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025.
- Revenue
- −107.3%
- EPS
- +83.6%
- Free cash flow
- +133.9%
Quarter to June 2026, against a year earlier
2.80
0.03
+1.08%
Follow NEUP
Alert me
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(7.55) | (7.14) | — | (8.42) | 1.06 | — | — | — | — | — |
P/S ratio |
1.23 | 0.74 | — | 574.69 | 1,463.61 | — | 558.54 | 558.54 | 558.54 | 558.54 |
P/FCF ratio |
0.00 | 50.41 | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(14.70) | (16.04) | — | (17.76) | 0.07 | — | (18.17) | — | (9.91) | — |
P/Operating CF |
15.83 | (3.21) | — | (14.99) | (39.96) | — | (135.99) | (135.99) | (135.99) | (135.99) |
Beneish M-Score |
831.96 | — | — | (7.82) | — | — | — | — | — | — |
P/B ratio |
0.78 | 0.61 | — | 0.00 | 15.27 | — | 21.54 | 21.54 | 21.54 | 21.54 |
Price to Tangible BV |
1.13 | 2.07 | — | 0.00 | 25.41 | — | 40.60 | 40.60 | 40.60 | 40.60 |
EV/Sales |
0.02 | (0.12) | — | 543.36 | 1,408.25 | — | 543.25 | 543.25 | 543.25 | 543.25 |
EV/EBITDA |
0.00 | 3.98 | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.02) | (24.05) | — | (4.49) | (19.13) | — | (80.32) | (80.32) | (80.32) | (80.32) |
EV/FCF |
(0.02) | (8.12) | — | (4.49) | (19.13) | — | (80.32) | (80.32) | (80.32) | (80.32) |
Quick Ratio |
27.33 | 3.39 | 3.33 | 4.57 | 12.02 | 12.74 | 0.91 | 1.69 | 2.60 | 3.84 |
Current Ratio |
27.85 | 3.56 | 3.45 | 4.87 | 12.46 | 13.10 | 1.01 | 1.82 | 2.70 | 3.92 |
Net Debt/EBITDA |
1.26 | 30.65 | 0.73 | 0.57 | 1.59 | 4.92 | (0.80) | (0.21) | 0.15 | 2.02 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.82% | 1.28% | 35.51% | 34.10% | 32.94% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.96 | 1.11 | 1.26 | 0.46 |
Asset Turnover |
0.04 | 0.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.12 | 0.25 |
Operating CF/Net income |
0.92 | (0.21) | 0.95 | 0.68 | 1.00 | 0.87 | 0.55 | 1.48 | 0.79 | 0.04 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | — | — | (1,115.89) | (496.67) | (5.15) | (12.67) | 0.00 | (25.18) | (9.33) |
| (61.70%) | (2.03%) | (78.44%) | (67.56%) | (41.08%) | (29.37%) | (47.24%) | (60.13%) | (85.08%) | (23.77%) | |
| (46.95%) | (1.31%) | (55.12%) | (56.31%) | (35.91%) | (20.26%) | (15.63%) | (16.91%) | (77.11%) | (9.20%) | |
ROIC |
(217.17%) | (14.97%) | (229.05%) | (138.68%) | (57.33%) | (24.03%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(66.23%) | (3.42%) | (165.40%) | (201.90%) | (56.58%) | (30.44%) | (625.07%) | (74.88%) | (98.84%) | (15.62%) |
Average Days of Receivables |
252.85 | 0.28 | 0.00 | 10,508.55 | 9,390.97 | 0.00 | 23,295.91 | 4,539.58 | 874.84 | 195.77 |
Research and Development Expense of Revenue |
301.94% | 57.54% | 0.00% | 88,322.30% | 6,067.59% | 0.00% | 12,479.23% | 1,729.15% | 672.61% | 131.30% |
Selling, General and Administrative Expense of Revenue |
633.55% | 49.67% | 0.00% | 60,211.49% | 2,805.85% | 0.00% | 8,231.69% | 966.61% | 154.71% | 35.46% |
Intangible Assets out of Total Assets |
0.27 | 0.47 | 0.51 | 0.52 | 0.35 | 0.41 | 0.71 | 0.48 | 0.40 | 0.00 |
Share Based Compensation of Revenue |
29.94% | 1.05% | 0.00% | 9,089.86% | 1,073.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.88 | 0.47 | — | 0.03 | 0.04 | — | 0.02 | 0.02 | 0.02 | 0.02 |
Graham Number |
0.00 | 0.00 | — | 0.42 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(115.33%) | (15.34%) | — | (0.10%) | (0.03%) | — | (0.01%) | (0.01%) | (0.01%) | (0.01%) |
Free Cash Flow Yield |
(63.52%) | 1.98% | — | (21.06%) | (5.03%) | — | (1.21%) | (1.21%) | (1.21%) | (1.21%) |
Revenue per Share |
0.27 | 9.64 | 0.00 | 0.02 | 0.31 | 0.00 | 0.13 | 2.03 | 12.45 | 61.63 |
Operating CF per Share |
(2.81) | 0.05 | (17.64) | (21.54) | (25.20) | (15.61) | (10.44) | (44.33) | (65.97) | (0.80) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(2.81) | 0.05 | (17.64) | (21.54) | (25.00) | (15.54) | (10.44) | (44.33) | (65.97) | (0.80) |
Cash per Share |
4.52 | 8.80 | 15.15 | 17.81 | 38.88 | 59.91 | 12.43 | 42.12 | 84.54 | 145.05 |
Shareholders Equity per Share |
5.60 | 11.71 | 21.02 | 32.38 | 65.93 | 98.55 | 34.43 | 47.81 | 56.26 | 135.13 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.60 | 11.71 | 21.02 | 32.38 | 65.93 | 98.55 | 34.43 | 47.81 | 56.26 | 135.13 |
Free Cash Flow |
(12.35) | 0.08 | (14.68) | (14.64) | (15.66) | (5.61) | (2.63) | (10.70) | (14.73) | (0.18) |
Working Capital |
20.31 | 10.82 | 9.36 | 10.59 | 27.90 | 21.34 | 0.04 | 7.92 | 16.77 | 31.22 |
Capital Expenditures |
— | — | — | — | 0.13 | 0.03 | (0.01) | (0.07) | (0.36) | (0.19) |
Net Current Asset Value |
16.96 | 5.45 | 3.04 | 6.77 | 24.24 | 18.13 | (9.21) | (8.41) | (9.03) | 8.35 |
EV/EBIT |
0.00 | 1.64 | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | (0.66) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 236.75 | 331.50 | 265.28 | 211.82 | 208.34 | 2.32 | 0.68 | 0.61 | 0.67 |
Cash ROIC |
(27.78%) | 0.23% | (48.78%) | (42.91%) | (23.71%) | (9.72%) | (13.03%) | (31.01%) | (31.13%) | (0.23%) |
Accounts Receivable Turnover |
2.85 | 225.50 | 0.00 | 0.01 | 0.07 | 0.00 | 0.01 | 0.08 | 0.39 | 1.99 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.41 | 0.07 | 0.28 | 2.67 | 2.88 | 1.44 | 4.07 | 6.38 | 7.14 | 7.14 |
Average Payables |
0.77 | 1.70 | 1.84 | 1.73 | 1.69 | 1.11 | 0.85 | 1.76 | 2.07 | 2.07 |
Average Inventory |
— | — | — | — | — | — | — | 0.41 | 0.35 | 0.35 |
Average Assets |
28.65 | 28.12 | 28.11 | 37.97 | 43.96 | 32.08 | 30.56 | 42.86 | 24.10 | 56.44 |
Average Common Equity |
21.80 | 18.25 | 19.75 | 31.65 | 38.43 | 22.13 | 10.11 | 12.05 | 21.84 | 21.84 |
Columns are period end dates · fundamentals updated 26 Oct 2026